" Endocrine News " Podcast Episode 69: Biosimilar Insulin

The Endocrine Society has several podcasts; one of its podcasts is known by the name of " Endocrine News " . Ordinarily, I ignore most of the Endocrine Society podcasts because: a) they tend to be disproportionately focused on the topic of Type 2 diabetes and treatments for that and b) even when the podcast subject matter includes Type 1 diabetes, I find alternative sources provide considerably more information on the same topics. Partly, it is because the Endocrine Society ' s Endocrine News podcast tends to be only about 10-30 minutes in length which is frequently insufficient to address the topics they aim to address. Still, I pay attention to their podcast topics and will occasionally listen if the topic is of interest. A recent episode featured an interview with Dr. Irl Hirsch, MD who is a professor of medicine at the University of Washington Medicine Diabetes Institute. In which he talks about biosimilar insulin: its safety, efficacy, what sets it apart from biologic insulin, and when it should be considered for use.Dr. Irl Hirsch, MDDr. Hirsch talks about insulin biosimilars as well as " authorized generic " versions of branded insulins (without calling them " authorized generics " ), but he also discusses the outlook for broader biosimilar insulin availability expected in 2024, where we can anticipate biosimilars of Sanofi Lantus from Sandoz/Gan& Lee, Lannett/HEC, Amphastar/ANP, and the nonprofit Civica/GeneSys Biologics, in addition to several on the ma...
Source: Scott's Web Log - Category: Endocrinology Tags: 2023 Biosimilar Biosomilars endocrine news episode insulin irl hirsch podcast podcast episode recommendations the endocrine society Source Type: blogs